Brefeldin-A-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemEBrefeldinACat.No.:HY-16592CASNo.:20350-15-6分?式:C??H??O?分?量:280.36作?靶點(diǎn):Autophagy;CRISPR/Cas9;Mitophagy;HSV;Antibiotic作?通路:Autophagy;CellCycle/DNADamage;Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)Ethanol:33.33mg/mL(118.88mM;Needultrasonic)掃描?維碼，DMSO:20.83mg/mL(74.30mM;Needultrasonic)運(yùn)?溶解?案計(jì)算器獲得適合您實(shí)驗(yàn)體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.5668mL17.8342mL35.6684mL5mM0.7134mL3.5668mL7.1337mL10mM0.3567mL1.7834mL3.5668mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存?式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶1.請(qǐng)依序添加每種溶劑：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.08mg/mL(7.42mM);Clearsolution此?案可獲得≥2.08mg/mL(7.42mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL20.8mg/mL的澄DMSO儲(chǔ)備液加到400μLPEG300中，混合均勻；向上述體系中加?50μLTween-80，混合均勻；然后繼續(xù)加?450μL?理鹽?定容?1mL。1/4www.MedChemEwww.MedChemE2.請(qǐng)依序添加每種溶劑：10%DMSO90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(7.42mM);Clearsolution此?案可獲得≥2.08mg/mL(7.42mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL20.8mg/mL的澄DMSO儲(chǔ)備液加到900μL20%的SBE-β-CD?理鹽??溶3.液中，混合均勻。請(qǐng)依序添加每種溶劑：10%DMSO90%cornoilSolubility:≥2.08mg/mL(7.42mM);Clearsolution此?案可獲得≥2.08mg/mL(7.42mM，飽和度未知)的澄溶液，此?案不適?于實(shí)驗(yàn)周期在半個(gè)?以上的實(shí)驗(yàn)。4.以1mL?作液為例，取100μL20.8mg/mL的澄DMSO儲(chǔ)備液加到900μL??油中，混合均勻。請(qǐng)依序添加每種溶劑：10%EtOH40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(8.92mM);Clearsolution此?案可獲得≥2.5mg/mL(8.92mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL25.0mg/mL的澄EtOH儲(chǔ)備液加到400μLPEG300中，混合均勻；向上述5.體系中加?50μLTween-80，混合均勻；然后繼續(xù)加?450μL?理鹽?定容?1mL。請(qǐng)依序添加每種溶劑：10%EtOH90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(8.92mM);Clearsolution此?案可獲得≥2.5mg/mL(8.92mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL25.0mg/mL的澄EtOH儲(chǔ)備液加到900μL20%的SBE-β-CD?理鹽??溶6.液中，混合均勻。請(qǐng)依序添加每種溶劑：10%EtOH90%cornoilSolubility:≥2.5mg/mL(8.92mM);Clearsolution此?案可獲得≥2.5mg/mL(8.92mM，飽和度未知)的澄溶液，此?案不適?于實(shí)驗(yàn)周期在半個(gè)?以上的實(shí)驗(yàn)。以1mL?作液為例，取100μL25.0mg/mL的澄EtOH儲(chǔ)備液加到900μL??油中，混合均勻。BIOLOGICALACTIVITY?物活性BrefeldinA(BFA)?種內(nèi)酯抗?素，蛋?質(zhì)運(yùn)輸?shù)奶囟ㄒ种苿?。BrefeldinA阻斷分泌蛋?和膜蛋?從內(nèi)質(zhì)?向?爾體的轉(zhuǎn)運(yùn)。BrefeldinA也?種?噬(autophagy)和mitophagy抑制劑。BrefeldinA還?種CRISPR/Cas9激動(dòng)劑，可抑制HSV-1病毒，并具有抗癌活性。IC50&TargetHSV-1CRISPR/Cas9體外研究BrefeldinA(BFA)treatmentfor15hor40h,causesdramaticswellingoftheEndoplasmicReticulum(ER)andshiftsitslocalizationtotheperipheryofnormalratkidney(NRK)cells.ProlongedBrefeldinAtreatmentresultsinmarkeddisruptionoftheMTandactincytoskeleton[1].ADP-ribosylationofBARSismediatedbyformationofaconjugatebetweenBrefeldinAandADPR.BARSshowsBACbindingwhenincubatedwiththemediumfromtheBFA-treatedCD38+HeLacells[3].BrefeldinAinducesanchorage-independentcelldeathinMDA-MB-231breastcancercells,inhibitstheformationofMDA-MB-231coloniesin3Dand2DculturesandinhibitsthemigrationandMMP9(MatrixMetallopeptidase9)activityofMDA-MB-231[2].PROTOCOL2/4www.MedChemEwww.MedChemECellAssay[1]Cellsaregrownonglasscoverslips,fixedin3%paraformaldehydeinPBS(10minatroomtemperature)andthenwashedinPBS.Cellsarepermeabilizedwith0.01%TritonX-lOOinPBSatroomtemperaturefor7min.Thecoverslipsarewashed(3timesinPBS/0.2%Tween)incubatedinPBS/O.4%fishskingelatin/0.2%Tween(5min)andinPBS/2.5%goatserum/0.2%Tween(5min.).Afterblocking,thecellsareincubatedwithprimaryantibodiesfor45minat37°C,andthenwashedwithPBS/0.2%Tween(5times,5mineach).Thesecondaryantibodiesareaddedfor30minat37°Candthencellsarewashedasabove.Coverslipsaremountedonslidesin9:1glycerol/PBSwith0.1%o-phenylenediamine.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CancerRes.2020Sep15;80(18):3892-3905.?JAutoimmun.2019May;99:39-47.?CellDeathDis.2020Nov11;11(11):969.?CellDeathDis.2018Nov16;9(12):1143.?PLoSPathog.2020Oct19;16(10):e1008947.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AlvarezC,etal.BrefeldinA(BFA)disruptstheorganizationofthemicrotubuleandtheactincytoskeletons.EurJCellBiol.1999Jan;78(1):1-14.[2].ColanziA,etal.MolecularmechanismandfunctionalroleofbrefeldinA-mediatedADP-ribosylationofCtBP1/BARS.ProcNatlAcadSciUSA.2013Jun11;110(24):9794-9.[3].TsengCN,etal.BrefeldinAreducesanchorage-independentsurvival,cancerstemcellpotentialandmigrationofMDA-MB-231humanbreastcancercells.Molecules.2014Oct29;19(11):17464-77.[4].WangJ,etal.Erythroleukemiacellsacquireanalternativemitophagycapability.SciRep.2016Apr19;6:24641.[5].YuC,etal.SmallmoleculesenhanceCRISPRgenomeeditinginpluripotentstemcells.CellStemCell.2015Feb5;16(2):142-7.[6].NozawaN,etal.Subcellularlocalizationofherpessimplexvirustype1UL51proteinandroleofpalmitoylationinGolgiapparatustargeting.JVirol.2003Mar;77(5):3204-16.[7].JensenHL,RygaardJ,NorrildB.Atime-relatedstudyofBrefeldinAeffectsinHSV-1infectedculturedhumanfibroblasts.APMIS.1995;103(7-8):530-539.doi:10.1111/j.1699-0463.1995.tb01402.xMcePdfHeight3/4www.MedChe